These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 36593968)

  • 41. BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia.
    Ramsey HE; Greenwood D; Zhang S; Childress M; Arrate MP; Gorska AE; Fuller L; Zhao Y; Stengel K; Fischer MA; Stubbs MC; Liu PCC; Boyd K; Rathmell JC; Hiebert SW; Savona MR
    Clin Cancer Res; 2021 Jan; 27(2):598-607. PubMed ID: 33148670
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diminished AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance.
    Ly M; Rentas S; Vujovic A; Wong N; Moreira S; Xu J; Holzapfel N; Bhatia S; Tran D; Minden MD; Draper JS; Hope KJ
    Cancer Res; 2019 Nov; 79(22):5799-5811. PubMed ID: 31519687
    [TBL] [Abstract][Full Text] [Related]  

  • 43. microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia.
    Han YC; Park CY; Bhagat G; Zhang J; Wang Y; Fan JB; Liu M; Zou Y; Weissman IL; Gu H
    J Exp Med; 2010 Mar; 207(3):475-89. PubMed ID: 20212066
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
    Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
    Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia.
    Xiang Z; Luo H; Payton JE; Cain J; Ley TJ; Opferman JT; Tomasson MH
    J Clin Invest; 2010 Jun; 120(6):2109-18. PubMed ID: 20484815
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis.
    Jin S; Cojocari D; Purkal JJ; Popovic R; Talaty NN; Xiao Y; Solomon LR; Boghaert ER; Leverson JD; Phillips DC
    Clin Cancer Res; 2020 Jul; 26(13):3371-3383. PubMed ID: 32054729
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
    Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
    J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Myeloid Targeted Human MLL-ENL and MLL-AF9 Induces cdk9 and bcl2 Expression in Zebrafish Embryos.
    Belt AJ; Grant S; Tombes RM; Rothschild SC
    PLoS Genet; 2024 Jun; 20(6):e1011308. PubMed ID: 38829886
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Zeb1 modulates hematopoietic stem cell fates required for suppressing acute myeloid leukemia.
    Almotiri A; Alzahrani H; Menendez-Gonzalez JB; Abdelfattah A; Alotaibi B; Saleh L; Greene A; Georgiou M; Gibbs A; Alsayari A; Taha S; Thomas LA; Shah D; Edkins S; Giles P; Stemmler MP; Brabletz S; Brabletz T; Boyd AS; Siebzehnrubl FA; Rodrigues NP
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33108352
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
    Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
    Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C.
    Zhu N; Chen M; Eng R; DeJong J; Sinha AU; Rahnamay NF; Koche R; Al-Shahrour F; Minehart JC; Chen CW; Deshpande AJ; Xu H; Chu SH; Ebert BL; Roeder RG; Armstrong SA
    J Clin Invest; 2016 Mar; 126(3):997-1011. PubMed ID: 26878175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia.
    Gao XN; Lin J; Li YH; Gao L; Wang XR; Wang W; Kang HY; Yan GT; Wang LL; Yu L
    Oncogene; 2011 Aug; 30(31):3416-28. PubMed ID: 21399664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
    Chen X; Glytsou C; Zhou H; Narang S; Reyna DE; Lopez A; Sakellaropoulos T; Gong Y; Kloetgen A; Yap YS; Wang E; Gavathiotis E; Tsirigos A; Tibes R; Aifantis I
    Cancer Discov; 2019 Jul; 9(7):890-909. PubMed ID: 31048321
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling.
    Chen L; Li D; Guo X; Cheng C; Wei X
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):195. PubMed ID: 37796705
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Myc-Miz1 signaling promotes self-renewal of leukemia stem cells by repressing Cebpα and Cebpδ.
    Zhang L; Li J; Xu H; Shao X; Fu L; Hou Y; Hao C; Li W; Joshi K; Wei W; Xu Y; Zhang F; Dai S; Breslin P; Zhang J; Zhang J
    Blood; 2020 Apr; 135(14):1133-1145. PubMed ID: 32040550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
    Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MiR-20a-5p functions as a potent tumor suppressor by targeting PPP6C in acute myeloid leukemia.
    Bao F; Zhang L; Pei X; Lian C; Liu Y; Tan H; Lei P
    PLoS One; 2021; 16(9):e0256995. PubMed ID: 34587164
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape.
    Chiarella E; Aloisio A; Scicchitano S; Todoerti K; Cosentino EG; Lico D; Neri A; Amodio N; Bond HM; Mesuraca M
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639154
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mouse acute leukemia develops independent of self-renewal and differentiation potentials in hematopoietic stem and progenitor cells.
    Dong F; Bai H; Wang X; Zhang S; Wang Z; Xie M; Zhang S; Wang J; Hao S; Cheng T; Ema H
    Blood Adv; 2019 Feb; 3(3):419-431. PubMed ID: 30733302
    [TBL] [Abstract][Full Text] [Related]  

  • 60. miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential.
    Meyer SE; Muench DE; Rogers AM; Newkold TJ; Orr E; O'Brien E; Perentesis JP; Doench JG; Lal A; Morris PJ; Thomas CJ; Lieberman J; McGlinn E; Aronow BJ; Salomonis N; Grimes HL
    J Exp Med; 2018 Aug; 215(8):2115-2136. PubMed ID: 29997117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.